IL-17 Inhibition in Spondyloarthritis: A Targeted Approach in Psoriatic Arthritis

Chairperson:

Philip Mease¹

Speakers:

Erik Lubberts,² Iain McInnes,³ Désirée van der Heijde⁴

1. Swedish Hospital Medical Centre and the University of Washington School of Medicine, Seattle, Washington, USA
2. Erasmus MC: University Medical Centre Rotterdam, Rotterdam, Netherlands
3. Institute of Infection, Immunity and Immunology, University of Glasgow, Glasgow, UK
4. Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands

Disclosure:

Philip Mease has received research grants, consultation fees and/or speaker honoraria from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB; Erik Lubberts has received support from Novartis, Roche, Janssen, AbbVie, NTRC, Ensemble Therapeutics Group, and Pieris AG; Iain McInnes has received research funding and honoraria from Janssen, Eli Lilly, Amgen, Pfizer, Bristol-Myers Squibb, and Novartis; Désirée van der Heijde has received consulting fees and/or research grants from AbbVie, Amgen, AstraZeneca, Augurex, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly, Galapagos, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, UCB, and Vertex, and is a director of Imaging Rheumatology BV.

Acknowledgements:

Writing assistance was provided by Dr Jill Powell, apothecom scopemedical Ltd.

Support:

The publication of this article was funded by Novartis. The views and opinions expressed are those of the authors and not necessarily of Novartis.

Citation:

EMJ Rheumatol. 2015;2[1]:55-64. DOI/10.33590/emjrheumatol/10314862. https://doi.org/10.33590/emjrheumatol/10314862.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.